Pacific Biosciences is trading 5.03% higher at $2.22, while major U.S. indexes are also higher, supporting a broader risk-on backdrop.
- The company’s press-release listing has no new announcement dated October 26; its latest listed collaboration news is dated October 19. Third-quarter results are scheduled for November 4.
- Recent investor attention has included a reported Stephens price-target increase and ARK share purchases, but available reports do not establish either as the direct cause of today’s move.